Navigation Links
New Funding Validates Importance of Divergence's Work on Nematodes

Divergence receives grant funding of $500,000 to prevent crop damage by nematodes as the Divergence and National Corn Growers Association continues collaboration.

(PRWEB) February 9, 2010 -- Divergence, Inc. announced today that the company has recently received two Small Business Innovation Research (SBIR) grants totaling $500,000, along with renewed funding from the National Corn Growers Association (NCGA), to support advancement of the company’s innovative work to prevent crop damage from nematodes. Parasitic nematode worms are the largest unsolved pest problem in agriculture, limiting the yield of crops worldwide and causing tens of billions of dollars in crop damage annually.

The U.S. Department of Agriculture (USDA) and the National Science Foundation (NSF) both awarded grants to the company, while the NCGA announced continuation of its funding to support work on nematode control in corn. The USDA issued a Phase II grant of $350,000 for development of crops with resistance to root knot nematodes. The NSF provided a Phase I grant of $150,000 for the development of novel, safe and effective nematicidal chemicals for crops, turf and ornamental plants discovered through Divergence’s powerful research platform, Harvest®.

“This combination of funding is a validation of the substantial progress Divergence has made in demonstrating the performance of our technologies in protecting crops from parasitic nematode damage,” said James P. McCarter, M.D., Ph.D., President and Chief Scientific Officer of Divergence. “We are excited at the possibilities for meeting growers’ and greens superintendants’ needs with an array of products, whether used alone or in an integrated fashion. Our portfolio of complementary biotechnology traits and agrochemicals with superior human and environmental safety offer outstanding potential to meet market needs for higher yielding and sustainable agriculture.”

The grant from the NSF is the third that Divergence has received based on Harvest®. “Harvest® is a revolutionary proprietary platform technology with broad utility in the development of agrochemicals and is the source of Divergence’s lead nematicide,” said McCarter. “The platform allows for more rapid and cost effective discovery of novel fungicides, insecticides and herbicides, as well as nematicides. Divergence is applying the platform to internal and collaboration projects in multiple product categories. We are confident of our continued discovery of leads that work through highly effective modes of action not currently used in commercial products. This progress is important as concerns of safety and resistance in a variety of markets increase.”

Divergence is also pleased to continue its productive relationship with NCGA. The collaboration, now in its eighth year, has successfully discovered technology with the potential to protect corn from the yield-reducing effects of parasitic nematode infection. “It is gratifying that NCGA believes in the great importance and high quality of the research being conducted at Divergence,” said McCarter. “The advancement of our work in the last year makes us increasingly confident that growers will have one or more safe and effective approaches to significantly reduce the damage to corn done by parasitic nematodes. These developments should lead to products for other major crop markets, as well.”

About Divergence
Divergence, Inc., a world leader in the application of genomics and informatics to agriculture and infectious disease, discovers and develops products for the safe and effective control of parasites. The company's initial focus is on parasitic nematodes, devastating unseen pests that cause billions of dollars in crop loss annually and widespread disease in humans and animals. The company’s innovative research platforms have broad potential for the discovery of superior products for sustainable food production and improved human and animal health. For more information visit Divergence's Web site at


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. NVHR: Stop Liver Cancer Dead in Its Tracks By Closing Funding Gap for Viral Hepatitis Education, Screening Programs
2. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
3. Zimmer Holdings Announces 2010 Funding for OMeGA Medical Grants Association
4. A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs
5. Palmer Labs Awarded U.S. Department of Energy Funding for Algae Biofuel Research
6. Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project
7. The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinsons Disease Treatments
8. Zyngenia, Inc. Raises $10 Million in Series A Funding
9. Collaboration of Indianas Health Information Exchanges, State Organizations Submits Application for Health Information Technology Stimulus Funding
10. BioNanomatrix Awarded Supplemental Funding to Accelerate Commercialization of Innovative Single-Molecule Analyzer
11. Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):